CYP2C19 and Stroke: There is now convincing research that CYP2C19 LoF carriers who have had a stroke are at a significantly higher risk of MACE when treated with clopidogrel.36, 37, 38 An early cost-effectiveness analysis demonstrated that routine patient genotyping after ischemic stroke could provide significant health and cost gains by preventing recurrent stroke.39